Who is sponsoring NCT04516577?

NCT04516577 is sponsored by Shanghai Pulmonary Hospital, Shanghai, China.

What drugs are being tested in NCT04516577?

Interventions in NCT04516577: Assesssing the severity of pulmonary alveolar proteinosis.

What condition does NCT04516577 study?

NCT04516577 studies Pulmonary Alveolar Proteinosis.

Is NCT04516577 still recruiting?

NCT04516577 is currently completed. Last updated 9 March 2022.

Last reviewed 2022-03-09 · How we verify

NCT04516577

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Updated Severity and Prognosis Score of Pulmonary Alveolar Proteinosis

Completed Last updated 9 March 2022

What this trial tests

trial testing Assesssing the severity of pulmonary alveolar proteinosis in Pulmonary Alveolar Proteinosis in 231 participants. Completed in 31 December 2021.

Timeline

1 January 2020

Primary endpoint
31 December 2021

31 December 2021

Quick facts

Lead sponsor	Shanghai Pulmonary Hospital, Shanghai, China
Status	Completed
Study type	OBSERVATIONAL
Enrollment	231
Start date	1 January 2020
Primary completion	31 December 2021
Estimated completion	31 December 2021
Sites	1 location across China

Drugs / interventions tested

Assesssing the severity of pulmonary alveolar proteinosis

Conditions studied

Pulmonary Alveolar Proteinosis — all drugs for Pulmonary Alveolar Proteinosis →

Sponsor

Shanghai Pulmonary Hospital, Shanghai, China

Who can join

18 and older, any sex, with Pulmonary Alveolar Proteinosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

By updating the chest HRCT scoring criteria of patients with pulmonary alveolar proteinosis, a new and more perfect system for evaluating the severity of alveolar proteinosis will be established.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Updated severity and prognosis score of pulmonary alveolar proteinosis: A multi-center cohort study in China.
Bai JW, Huang JN, Shi SY, Ge A, et al · · 2023 · cited 6× · PMID 36824611 · DOI 10.3389/fmed.2023.1058001

Verify or expand the search:

Other Shanghai Pulmonary Hospital, Shanghai, China trials

Trials by the same sponsor.

NCT07469488 — A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-M · Phase 4 · not yet recruiting
NCT07494591 — TEAS for Ipsilateral Shoulder Pain After Video-Assisted Thoracoscopic Lung Surgery · NA · not yet recruiting
NCT07517640 — Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial · Phase 2 · not yet recruiting
NCT07393438 — Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS) · Phase 2 · not yet recruiting
NCT07375979 — A Multi-modal Integrating Imaging and Cell-free DNA Methylation in Lung Cancer Early Detection (CMe-Lung): a Multi-cente · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04516577 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Pulmonary Hospital, Shanghai, China
Last refreshed: 9 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04516577.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing